2020 has been a challenging year for all industries. For pharma and its HCP customers even more so. All eyes are on the companies developing vaccines and drugs for treatment of COVID-19, while doctors have closed their doors for pharma reps. Long established processes have been disrupted and complex market strategies have been rendered useless. Each pharma no matter big or small, innovative, or generic, had to improvise and come up with contingency plans to save the year. Some have been slower waiting for the old ways to come back, others have been more agile experimenting with digital and expanding boundaries, most are in the middle digitally curious but not risking too much.

With over 25 years of leadership experience across commercial...

Pharmaceutical & medical devices Industry is fast adapting to these changes at various levels of the value chain. Billions of dollars are being spent on digital transformation projects ranging from usage of AI & ML in product development, production and predictive maintenance, Blockchain in supply chain and data management & analytics in strategic decision making. This article focuses on Omnichannel marketing, one of the key digital transformations that the industry is learning and implementing at a rapid pace. Omnichannel Marketing: Promise and Possibilities An industry that historically focused all their brand building and market shaping efforts through F2F meetings & medical education programs has started making giant strides in multi-channel strategy now. A digital journey that started with an e-detailing platform has progressed fast by adding brand websites, Approved E-Mails, social media, webinars and other media effectively creating a multi-channel strategy. The only hindside to this is, all these channels work independently, expecting HCPs to find and sort out information themselves.

The last issue of 2016, with articles from K. Hariram and Vivek Hattangadi and new authors, Dr. Ashwin Bonde and Diksha Fouzdar. Diksha's article is the highlight of this issue - an in-depth look at how to embed compliance in the very DNA of a pharma company.

The first time I heard the term ‘digital economy’...

India has two very different pharmaceutical regulators living inside...

🚀 The Mega-Merger That Wasn't Early August saw the...

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

GLP-1 medicines such as semaglutide and tirzepatide are changing...

Beyond the Pharmacy of the World: Why India's Biopharma...

India has two very different pharmaceutical regulators living inside...

🚀 The Mega-Merger That Wasn't Early August saw the...

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

GLP-1 medicines such as semaglutide and tirzepatide are changing...

Beyond the Pharmacy of the World: Why India's Biopharma...

India has two very different pharmaceutical regulators living inside...

🚀 The Mega-Merger That Wasn't Early August saw the...

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

GLP-1 medicines such as semaglutide and tirzepatide are changing...

Beyond the Pharmacy of the World: Why India's Biopharma...

India has two very different pharmaceutical regulators living inside...

🚀 The Mega-Merger That Wasn't Early August saw the...

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

GLP-1 medicines such as semaglutide and tirzepatide are changing...

Beyond the Pharmacy of the World: Why India's Biopharma...